{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"This outcome was originally defined as a Kaplan-Meier estimate of overall survival (OS) and was defined as the time between first date of dosing of study medication and death due to any cause. However due to the early study termination and limited follow-up time, the majority of participants were censored for OS analysis. Data reported instead represent the number of participants who died due to any cause from Day 1 up to data cut-off.","groups":[{"description":"High risk, transplant non-eligible \\[TNE\\], newly diagnosed multiple myeloma (NDMM) participants who were administered • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \\[CrCl\\] value) on Days 1 to 21 of each 28-day treatment cycle • Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG000","title":"Cohort A: High Risk, TNE"},{"description":"\\>= 65 years old, transplant non-eligible \\[TNE\\], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \\[CrCl\\] value) on Days 1 to 21 of each 28-day treatment cycle • Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles.","id":"OG001","title":"Cohort B: >=65 Years Old, TNE"},{"description":"High risk, post-transplant NDMM participants were administered the following as maintenance therapy: • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle.","id":"OG002","title":"Cohort C: High Risk, Post-transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"Day 1 up to Week 87","title":"Participants Who Died Up To Data Cut-off Date (15 December 2017)","type":"SECONDARY","unitOfMeasure":"Participants"}